In Reply: Drs Giugliano and Esposito describe as scanty the data supporting our conclusion that all (noninsulin) drug classes added to stable and maximal metformin achieve similar rates of HbA1c less than 7%. We share their concern that only 52% of included trials reported this end point, as it may suggest the presence of selective outcome reporting in some trials. Unfortunately, selective outcome reporting occurs too often in medical studies; meta-analyses based on these studies are subject to some degree of publication bias, since they may be drawing conclusions on less than all the data.1
Coleman CI, Phung OJ, Scholle JM. Adding Noninsulin Antidiabetic Drugs to Metformin Therapy for Type 2 Diabetes—Reply. JAMA. 2010;304(4):405–407. doi:10.1001/jama.2010.1022
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: